Subscribe: Market Wire - Pharmaceuticals and Biotech: Drugs
http://img.marketwire.com/rss/mwPBDR.rss
Preview: Market Wire - Pharmaceuticals and Biotech: Drugs

Marketwired - Drugs



Marketwired - Drugs



Last Build Date: Mon, 22 Jan 2018 17:36:36 EST

Copyright: Copyright: (C) Marketwired
 



Acasti Pharma Announces the Closing of Over-Allotment Option for its Public Offering of Common Shares

Mon, 22 Jan 2018 17:05:00 EST

LAVAL, QUÉBEC--(Marketwired - Jan. 22, 2018) - Acasti Pharma Inc. (NASDAQ:ACST)(TSX VENTURE:ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia, today announced that the underwriters of its offering of 9,900,990 common shares, together with warrants to purchase up to 8,910,891 common shares (the "Offering") have given notice to exercise their over-allotment option by purchasing an additional 766,179 common shares at a price of US$1.01 per share, for additional gross proceeds to Acasti of approximately US$773,000. Closing of the exercise of the over-allotment option occurred on Monday, January 22, 2018.




UPDATE - Osage University Partners Announces Multiple Promotions

Mon, 22 Jan 2018 12:57:59 EST

BALA CYNWYD, PA --(Marketwired - January 22, 2018) - Osage University Partners, a venture capital fund that invests in university startups, today announced multiple promotions today in several key positions.




Osage University Partners Announces Multiple Promotions

Mon, 22 Jan 2018 09:00:00 EST

BALA CYNWYD, PA--(Marketwired - January 22, 2018) - Osage University Partners, a venture capital fund that invests in university startups, today announced multiple promotions today in several key positions.




VistaGen Therapeutics to Provide Update on Phase 2 Study for Major Depressive Disorder and Outline Key 2018 Initiatives at the 14th Annual Noble Capital Markets' Investor Conference

Mon, 22 Jan 2018 08:30:00 EST

SOUTH SAN FRANCISCO, CA--(Marketwired - January 22, 2018) - VistaGen Therapeutics Inc. (NASDAQ: VTGN), a clinical-stage biopharmaceutical company focused on developing new generation medicines for depression and other central nervous system (CNS) disorders, announced today that Shawn Singh, Chief Executive Officer of VistaGen, will provide an update on the Company's Phase 2 study of AV-101 as an oral new generation adjunctive treatment for Major Depressive Disorder (MDD) and outline key 2018 initiatives at the 14th Annual Noble Capital Markets' Investor Conference - NobleCon14 - to be held at the W Fort Lauderdale hotel in Fort Lauderdale, FL on Monday, January 29th at 4:30 p.m. ET.




Solis Tek Applauds California Pesticide Ban for Cannabis Cultivation

Mon, 22 Jan 2018 08:00:00 EST

Solis Tek's New Nutrient Division is Committed to Creating Safe, Organic Products to Enhance Cannabis Growth and Meet the Rigorous Requirements of States like California




Neptune annonce une entente de recherche visant à développer de nouveaux produits de santé et de mieux-être à base de cannabinoïdes

Fri, 19 Jan 2018 08:00:00 EST

LAVAL, QUÉBEC--(Marketwired - 19 jan. 2018) - Neptune Technologies & Bioressources inc. (« Neptune » ou la « Société ») (NASDAQ:NEPT)(TSX:NEPT) a annoncé aujourd'hui une entente de recherche exclusive ayant pour but de mettre au point de nouveaux produits de santé et de mieux-être à base de cannabinoïdes, comme le cannabidiol (CBD), qui contiendront également de l'huile de krill dont l'utilisation combinée serait exclusive à Neptune. Le marché visé est le nombre toujours croissant des juridictions fédérales à travers le monde qui ont ou auront légalisé la consommation de produits du cannabis par les adultes ou à des fins médicales, dont le Canada.




Neptune Announces Research Agreement Aimed at New Medical and Wellness Cannabinoid-based Products

Fri, 19 Jan 2018 08:00:00 EST

LAVAL, QUÉBEC--(Marketwired - Jan. 19, 2018) - Neptune Technologies & Bioressources Inc. ("Neptune" or the "Corporation") (NASDAQ:NEPT)(TSX:NEPT) today announced an exclusive research agreement with the purpose of developing new medical and wellness targeted cannabinoid-based products, such as cannabidiol ("CBD"), combined with krill oil whose combination use would be exclusive to Neptune. The new products will be aimed at the growing number of federal jurisdictions worldwide that have or will legalize cannabinoids, such as Canada, for medicinal and/or adult use.




Canopy Growth Corporation Announces Increase to Bought Deal Financing

Thu, 18 Jan 2018 15:27:51 EST

SMITHS FALLS, ONTARIO--(Marketwired - Jan. 18, 2018) -




Nuuvera Inc. Announces $35MM Bought Deal Offering

Thu, 18 Jan 2018 08:08:07 EST

TORONTO, ONTARIO--(Marketwired - Jan. 18, 2018) -




Nuuvera Acquires One of Seven Italian Cannabis Licenses

Thu, 18 Jan 2018 07:37:21 EST

Becomes first Canadian company to hold license to import cannabis




Canopy Growth Corporation Announces $175 Million Bought Deal Financing

Wed, 17 Jan 2018 17:27:29 EST

SMITHS FALLS, ONTARIO--(Marketwired - Jan. 17, 2018) -




Newstrike Announces Shareholder Approval of Plan of Arrangement with CanniMed

Wed, 17 Jan 2018 16:00:28 EST

TORONTO, ONTARIO--(Marketwired - Jan. 17, 2018) - Newstrike Resources Ltd. (TSX VENTURE:HIP) ("Newstrike" or the "Company") is pleased to announce that at an annual and special meeting of its shareholders held today (the "Meeting"), its shareholders overwhelmingly approved the previously announced proposed plan of arrangement (the "Plan of Arrangement") with CanniMed Therapeutics Inc. ("CanniMed"), pursuant to which CanniMed will acquire all of the outstanding common shares of Newstrike (the "Common Shares"). Of those votes cast with respect to the Plan of Arrangement, an aggregate of 271,880,416 Common Shares, representing approximately 99.40% of the votes cast by the shareholders at the Meeting or represented by proxy, were voted in support of the resolution. In addition, an aggregate of 239,517,680 Common Shares, representing approximately 99.30% of the votes cast by the shareholders at the meeting or represented by proxy excluding certain insiders, were voted in support of the resolution.




Rennova Health's Epic Reference Labs Receives Accreditation From College of American Pathologists

Wed, 17 Jan 2018 09:20:00 EST

WEST PALM BEACH, FL--(Marketwired - January 17, 2018) - Rennova Health, Inc. (OTCQB: RNVA), (OTCQB: RNVAW) ("Rennova" or the "Company"), a vertically integrated provider of industry-leading diagnostics and supportive software solutions to healthcare providers, that opened its first rural hospital in Oneida, Tenn. in August 2017, announces that its flagship Laboratory, EPIC Reference Labs, Inc. (EPIC) has successfully met the Laboratory Accreditation Program Standards for Accreditation from the College of American Pathologists (CAP). EPIC has been operating as a urine toxicology testing laboratory in Riviera Beach, Fla. since 2015.




Scythian Biosciences Corp. Announces Increase to Bought Deal Financing With Serruya Private Equity and the Delavaco Group as Other Strategic Investors

Wed, 17 Jan 2018 09:16:48 EST

TORONTO, ONTARIO--(Marketwired - Jan. 17, 2018) -




Leading Leukemia Experts Join Moleculin's Science Advisory Board

Wed, 17 Jan 2018 08:30:00 EST

HOUSTON, TX--(Marketwired - January 17, 2018) - Moleculin Biotech, Inc., (NASDAQ: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of anti-cancer drug candidates, some of which are based on license agreements with The University of Texas System on behalf of the MD Anderson Cancer Center ("MD Anderson"), today announced the expansion of its Science Advisory Board to include Drs. Jorge Cortes and Elihu Estey.




NutraFuels, Inc. (NTFU) Year End 2017 Corporate Update

Wed, 17 Jan 2018 08:00:00 EST

COCONUT CREEK, FL--(Marketwired - January 17, 2018) - NutraFuels Inc. ("NutraFuels" or "NTFU"), (OTC PINK: NTFU), today announced the following corporate update.




Neptune présente ses recommandations aux consultations particulières sur le projet de loi 157 à l'Assemblée nationale

Wed, 17 Jan 2018 08:00:00 EST

Une entreprise québécoise à l'expertise unique dans l'extraction d'huile a des visées mondiales en matière de cannabis




Neptune makes its recommendations on Bill 157 special consultations at the National Assembly

Wed, 17 Jan 2018 08:00:00 EST

A Quebec company with unique expertise in oil extraction has global objectives for cannabis




Trillium Therapeutics Enhances Senior Management Team to Support Further Clinical Development of TTI-621

Wed, 17 Jan 2018 07:00:00 EST

TORONTO, ONTARIO--(Marketwired - Jan. 17, 2018) - Trillium Therapeutics Inc. (NASDAQ:TRIL)(TSX:TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced the following key additions to its leadership team:




Aurquest Resources Inc. and Xanthic Biopharma Limited Announces Closing of $1,500,000 Private Placement

Wed, 17 Jan 2018 07:00:00 EST

TORONTO, ONTARIO--(Marketwired - Jan. 17, 2018) -




Harvest One Announces Filing of Preliminary Short Form Prospectus in Connection with $35 Million Bought Deal Financing and Appointment of Interim COO

Tue, 16 Jan 2018 23:28:26 EST

VANCOUVER, BRITISH COLUMBIA--(Marketwired - Jan. 16, 2018) -




EnWave Provides Corporate Update and Announces Amendment to its Consulting Agreement with Adelaide Capital Markets

Tue, 16 Jan 2018 09:00:00 EST




Tetra Bio-Pharma Receives Approval from Health Canada of its Phase 1 Clinical Trial with PPP005 (Cannabis Oil)

Tue, 16 Jan 2018 08:00:00 EST

OTTAWA, ONTARIO--(Marketwired - Jan. 16, 2018) - Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug development and discovery, is pleased to announce that it has received a No Objection Letter (NOL) from the Therapeutic Products Directorate (TPD), Health Canada to evaluate the safety, pharmacokinetics and pharmacodynamics of its cannabis oil PPP005.




CTD Holdings' European Clinical Trial Adopted by National Institute for Health Research of England

Tue, 16 Jan 2018 08:00:00 EST

Collaboration Will Provide Infrastructure Support to Study




Acasti Pharma Announces Change to Board of Directors

Tue, 16 Jan 2018 08:00:00 EST

LAVAL, QUÉBEC--(Marketwired - Jan. 16, 2018) - Acasti Pharma Inc. (NASDAQ:ACST)(TSX VENTURE:ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia, today announced that Neptune's representatives, Rick Schottenfeld and Katherine Crewe, have resigned from Acasti's Board of Directors.




BioVie Reviews Key Accomplishments in 2017 and Updates on Phase 2a Clinical Trial Progress

Tue, 16 Jan 2018 07:00:00 EST

BEVERLY, MA--(Marketwired - January 16, 2018) - BioVie Inc. (OTCQB: BIVI), a clinical-stage company focused on the development and commercialization of innovative drug therapies for liver disease, today reviewed key milestones achieved over the past year and provided a general update on the progress of its mid-stage (Phase 2a) clinical trial of BIV201 in refractory ascites patients.